Shares of Epizyme Inc. were up 11.0% in premarket trading on Friday after SVB Leerink upgraded the company’s stock to outperform, from market perform, citing Tazverik’s potential opportunity in the follicular lymphoma market. Analyst Andrew Berens told investors that the drug’s potential as a “maintenance” therapy could represent a “significant upside to current valuation.” (Maintenance treatments can be used to prevent relapses of some cancers.) Berens said he had previously estimated the drug could generate $252 million in sales in 2030; now he sees the potential for $854 million in sales, including sales from both treatment and maintenance prescriptions. The Food and Drug Administration approved Tazerik as a therapy for relapsed or refractory follicular lymphoma in June of last year. Epizyme’s stock is down 37.3% for the year, while the S&P 500 is up 11.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
